Related references
Note: Only part of the references are listed.Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Kathleen K. Christians et al.
ONCOLOGIST (2014)
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
R. Alvarez et al.
BRITISH JOURNAL OF CANCER (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
Wei-Chih Liao et al.
LANCET ONCOLOGY (2013)
Advanced-stage pancreatic cancer: therapy options
Jens Werner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers
Christina H. Wei et al.
PANCREAS (2013)
Going with the Flow: From Circulating Tumor Cells to DNA
Francois-Clement Bidard et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
J. B. Bachet et al.
ANNALS OF ONCOLOGY (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew H. G. Katz et al.
CANCER (2012)
Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
Hiroshi Haeno et al.
CELL (2012)
Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
David A. Tuveson et al.
CELL (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
Targeted therapies: how personal should we go?
Miriam Martini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
Mert Erkan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
New biomarkers and targets in pancreatic cancer and their application to treatment
Eithne Costello et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Kian-Huat Lim et al.
ONCOLOGIST (2012)
Phase II Study of Radiation Therapy Combined With Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer
Keiko Shibuya et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Arterial Resection During Pancreatectomy for Pancreatic Cancer A Systematic Review and Meta-Analysis
Nathan Mollberg et al.
ANNALS OF SURGERY (2011)
Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer
Jayme B. Stokes et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
Manish Patel et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
Tumoral and Nontumoral Pancreas: Correlation between Quantitative Dynamic Contrast-enhanced MR Imaging and Histopathologic Parameters
Maria A. Bali et al.
RADIOLOGY (2011)
Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
M. Mura Assifi et al.
SURGERY (2011)
A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer
Alessio G. Morganti et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
ESTIMATING OPTIMAL DOSE OF TWICE-WEEKLY GEMCITABINE FOR CONCURRENT CHEMORADIOTHERAPY IN UNRESECTABLE PANCREATIC CARCINOMA: MATURE RESULTS OF GEMRT-01 PHASE I TRIAL
Nicolas Girard et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Pancreatic Cancer: Utility of Dynamic Contrast-enhanced MR Imaging in Assessment of Antiangiogenic Therapy
M. Fatih Akisik et al.
RADIOLOGY (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer
Hiroaki Ohigashi et al.
ANNALS OF SURGERY (2009)
AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the Conference
Jean-Nicolas Vauthey et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
Raphael Marechal et al.
CLINICAL CANCER RESEARCH (2009)
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Amanda Blackford et al.
CLINICAL CANCER RESEARCH (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Redefining resection margin status in pancreatic cancer
Caroline S. Verbeke et al.
HPB (2009)
Perioperative management of pancreatic cancer
V. Heinemann et al.
ANNALS OF ONCOLOGY (2008)
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity Results of a Prospective Phase II Trial
Stefan Heinrich et al.
ANNALS OF SURGERY (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R. Varadhachary et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial
William Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
Douglas B. Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
Matthew H. G. Katz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Pancreatic perfusion:: Noninvasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers -: Initial results
Maria Antonietta Bali et al.
RADIOLOGY (2008)
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation - Long-term results of EORTC trial 40891
Hans G. Smeenk et al.
ANNALS OF SURGERY (2007)
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
Daniel H. Palmer et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Full-dose genicitabine and concurrent radiotherapy for unresectable pancreatic cancer
James D. Murphy et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942
Michael G. Haddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience
Jordan M. Winter et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2006)
Pancreatic resections after chemo radiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival
Paolo Massucco et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy
Gauri R. Varadhachary et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities histologic response rates, and event-free outcome
PWT Pisters et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial
JP Neoptolemos et al.
ANNALS OF SURGERY (2001)
Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
VK Mehta et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators
TA Sohn et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2000)
Share Paper
